^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ARID2 (AT-Rich Interaction Domain 2)

    i
    Other names: ARID2, AT-Rich Interaction Domain 2, BAF200, AT-Rich Interactive Domain-Containing Protein 2, AT Rich Interactive Domain 2 (ARID, RFX-Like), Zinc Finger Protein With Activation Potential, ARID Domain-Containing Protein 2, BRG1-Associated Factor 200, Zipzap/P200, DKFZp686G052, FLJ30619, CSS6
    10d
    Giant cutaneous melanoma presenting with hemorrhagic complications. (PubMed, Acta Dermatovenerol Alp Pannonica Adriat)
    This case underscores the urgent need for timely recognition and intervention in giant melanoma with acute complications. It also highlights the effectiveness of modern adjuvant therapies in improving prognosis.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ARID2 (AT-Rich Interaction Domain 2)
    |
    BRAF V600 • PTEN mutation
    19d
    Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma. (PubMed, Sci Rep)
    This finding highlights the functional relevance of IMiD's inherent polypharmacology in circumventing primary resistance mechanisms at the cellular level. Together, our results identify the ARID2-containing PBAF complex as a critical vulnerability in resistant myeloma cells and provide a mechanistic rationale for designing combination strategies that co-target this complex, with the potential to enhance therapeutic efficacy by overcoming drug resistance.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • ARID2 (AT-Rich Interaction Domain 2) • IRF4 (Interferon regulatory factor 4)
    |
    pomalidomide • Farydak (panobinostat)
    1m
    Analysis of SWI Complex Subunits in 69 Cases of TTF-1 Negative Non-Small Cell Lung Carcinoma. (PubMed, Diagn Cytopathol)
    The uniqueness of this study lies in the large number of cases, with their specimens obtained via cytopathological methods and immunostained with all five common SWI markers. This study contributes to the familiarity and awareness of pathologists and oncologists by highlighting the importance of cytomorphology and immunohistochemical profile of SWI/SNF-deficient NSCLC-NOS, facilitating earlier diagnosis, and may ultimately lead to more specific and novel therapeutic targets.
    Journal
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • ARID1B (AT-Rich Interaction Domain 1B) • ARID2 (AT-Rich Interaction Domain 2) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    1m
    Genetic profiling of mammary periductal stromal tumors with histologic correlation highlights high-grade and low-grade groups and similarities to phyllodes tumors. (PubMed, Mod Pathol)
    In summary, we describe herein the genetic landscape of PDST, demonstrate correlation of genetic features with high-grade versus low-grade histology, and identify TP53 among key oncogenic drivers of HGPDST, including in Li-Fraumeni Syndrome. The genetics of HGPDST overlap with borderline or malignant PT, consistent with their classification as PT variants that arise through a MED12-independent pathway.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CD34 (CD34 molecule) • ARID2 (AT-Rich Interaction Domain 2) • HMGA2 (High mobility group AT-hook 2) • KMT2B (Lysine Methyltransferase 2B) • LZTR1 (Leucine Zipper Like Transcription Regulator 1)
    1m
    Genetic Evolution of Melanoma: Comparative Analysis of Candidate Gene Mutations in Healthy Skin, Nevi, and Tumors from the Same Patients. (PubMed, Int J Mol Sci)
    Melanoma-private mutations in genes such as ARID1A, ARID2, PIK3CA, and CDKN2A indicated additional late events contributing to malignant progression. Overall, this study supports a model in which many melanomas evolve from pre-existing nevi through sequential acquisition and clonal amplification of somatic mutations, while also revealing heterogeneous evolutionary trajectories.
    Clinical • Journal • Tumor mutational burden
    |
    BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • ARID2 (AT-Rich Interaction Domain 2)
    |
    BRAF V600E • NRAS mutation • PIK3CA mutation • BRAF V600 • ARID1A mutation • NRAS Q61
    2ms
    DMTF1 up-regulation rescues proliferation defect of telomere dysfunctional neural stem cells via the SWI/SNF-E2F axis. (PubMed, Sci Adv)
    Accordingly, Arid2 or Ss18 depletion phenocopies DMTF1 loss in reducing H3K27ac levels, expression of E2F target genes, and NSC proliferation. Thus, our study has identified DMTF1 as a potential therapeutic target to reverse the proliferation defect of aged NSC that is modeled by telomere attrition and unearthed a distinct genetic program controlled by DMTF1 in NSC.
    Journal
    |
    ARID2 (AT-Rich Interaction Domain 2) • MELTF (Melanotransferrin) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • MTF1 (Metal Regulatory Transcription Factor 1)
    2ms
    SWI/SNF complex alterations predict immunotherapy response in bladder cancer. (PubMed, Front Immunol)
    SWI/SNF alterations define an immunotherapy-responsive stratification of UBC. The accompanying genotype-specific prognostic models provide a ready-to-test framework for guiding precision immunotherapy.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • ARID1B (AT-Rich Interaction Domain 1B) • ARID2 (AT-Rich Interaction Domain 2)
    3ms
    Genomic pathogenic alterations in the SWI/SNF complex compromise the outcomes of immunotherapy in Chinese patients with KRAS-mutant NSCLC by downregulating STING expression. (PubMed, BMC Med)
    In KRAS-mut NSCLCs with or without STK11/KEAP1 mutations, the GPAs in the DNA-binding genes ARID1A/ARID2 affected the outcomes of immunotherapy, possibly through the downregulation of STING expression.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • KEAP1 (Kelch Like ECH Associated Protein 1) • PBRM1 (Polybromo 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • ARID1B (AT-Rich Interaction Domain 1B) • STING (stimulator of interferon response cGAMP interactor 1) • ARID2 (AT-Rich Interaction Domain 2)
    |
    KRAS mutation • EGFR wild-type • ARID1A mutation • STK11 mutation • KEAP1 mutation
    3ms
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    3ms
    Genetic evolution of keratinocytes to cutaneous squamous cell carcinoma. (PubMed, Nat Commun)
    Surprisingly, actinic keratoses are often not related to their neighboring cSCC. Spatial analyses reveal gene expression heterogeneity, including checkpoint molecule enrichment at invasive fronts, highlighting tumor and immune cell interactions.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • TERT (Telomerase Reverse Transcriptase) • ARID2 (AT-Rich Interaction Domain 2)
    |
    TP53 mutation • TMB-L
    3ms
    Arid2 promotes Follicular B-cell differentiation and antibody responses in vivo. (PubMed, bioRxiv)
    Functionally, Arid2-deficient mice exhibited impaired germinal center expansion after immunization and reduced IgG antibody production following transplantation. Together, these findings identify Arid2 as a critical regulator of B cell differentiation and maturation by coordinating transcriptional programs during early lymphopoiesis.
    Preclinical • Journal
    |
    ARID2 (AT-Rich Interaction Domain 2)
    4ms
    Deciphering Cancer Evolution Through Genomic Profiling of Patient-Derived Xenograft Together with Matched Primary Gallbladder Cancer. (PubMed, Dig Dis Sci)
    We successfully established a PDX model of gallbladder adenosquamous carcinoma, with KRAS (G12V) identified as a potential initiating mutation, and the probable tumor-initiating cell is derived from an EpCAM-positive putative cancer stem cell. Sequential analysis revealed the emergence of resistant clones and adaptive selection of chromatin remodelers in the PDX model.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ARID1A (AT-rich interaction domain 1A) • BAP1 (BRCA1 Associated Protein 1) • LRP1B (LDL Receptor Related Protein 1B) • MUC1 (Mucin 1) • ARID2 (AT-Rich Interaction Domain 2) • EPCAM (Epithelial cell adhesion molecule) • TP63 (Tumor protein 63) • AQP1 (Aquaporin 1) • MUC5AC (Mucin 5AC) • S100P (S100 calcium binding protein P)
    |
    KRAS mutation • PIK3CA mutation • ARID1A mutation • KRAS G12